Pacira BioSciences (NASDAQ: PCRX) grants CFO 49,091 restricted stock units

Rhea-AI Filing Summary

Pacira BioSciences Chief Financial Officer Shawn Cross was granted 49,091 restricted stock units of common stock on February 11, 2026. The award was reported at a price of $0 per share as an acquisition, increasing his directly held common stock to 105,341 shares.

The restricted stock units vest in four equal annual installments beginning on February 15, 2027, if Cross remains in continuous service with Pacira on each vesting date. Each unit represents the right to receive one share of Pacira common stock upon vesting.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Cross Shawn

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	49,091	$0.00	--

Holdings After Transaction: Common Stock — 105,341 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cross Shawn

(Last) (First) (Middle)

C/O PACIRA BIOSCIENCES, INC.

2000 SIERRA POINT PARKWAY, SUITE 900

(Street)

BRISBANE CA 94005

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Pacira BioSciences, Inc. [ PCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/11/2026		A		49,091(1)	A	$0	105,341	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units that vest in four equal annual installments beginning on February 15, 2027, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.

Remarks:

	/s/ Kristen Williams, Attorney-in-Fact	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Pacira BioSciences (PCRX) report for its CFO?

Pacira BioSciences reported an equity grant to its CFO Shawn Cross. On February 11, 2026, he was awarded 49,091 restricted stock units of common stock at a reported price of $0 per share, classified as an acquisition under a compensation-type grant.

How many Pacira (PCRX) shares does CFO Shawn Cross own after this Form 4?

After the reported grant, CFO Shawn Cross beneficially owns 105,341 Pacira common shares. This total reflects the addition of 49,091 restricted stock units reported as acquired in the filing, all held as direct ownership according to the Form 4 data.

How do the Pacira (PCRX) restricted stock units granted to the CFO vest?

The 49,091 restricted stock units vest in four equal annual installments. Vesting begins on February 15, 2027, and each tranche requires Shawn Cross to remain in continuous service with Pacira through the applicable vesting date to receive the underlying common shares.

Does the Pacira (PCRX) Form 4 show an open-market stock purchase or sale?

The Form 4 reports an equity grant, not an open-market trade. The transaction code is “A” for a grant, award, or other acquisition at a price of $0 per share, indicating compensation-related restricted stock units rather than a market buy or sell.

What does each restricted stock unit in the Pacira (PCRX) CFO grant represent?

Each restricted stock unit represents a contingent right to one common share. When the units vest on scheduled annual dates starting February 15, 2027, and service conditions are met, they convert into equivalent shares of Pacira BioSciences common stock for the reporting person.